Twice-Daily Dolutegravir Based Antiretroviral Therapy with One Month of Daily Rifapentine and Isoniazid (1HP) for TB Prevention.

Podany, Anthony T; Cramer, Yoninah; Imperial, Marjorie; Rosenkranz, Susan L; Avihingsanon, Anchalee; Arduino, Roberto; Samaneka, Wadzanai; Gelmanova, Irina; Savic, Rada; Swindells, Susan; Dawson, Rodney; Luetkemeyer, Anne F.

Afiliação

Podany AT; University of Nebraska Medical Center, College of Pharmacy, Omaha, NE, USA.
Cramer Y; Harvard School of Public Health, Statistical & Data Analysis Center, Boston, MA, USA.
Imperial M; University of California San Francisco, College of Pharmacy, San Francisco, CA, USA.
Rosenkranz SL; Harvard School of Public Health, Statistical & Data Analysis Center, Boston, MA, USA.
Avihingsanon A; Thai Red Cross AIDS Research Center, Bangkok, Thailand.
Arduino R; The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
Samaneka W; University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe.
Gelmanova I; Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
Savic R; University of California San Francisco, College of Pharmacy, San Francisco, CA, USA.
Swindells S; University of Nebraska Medical Center, Infectious Diseases, Internal Medicine, Omaha, NE, USA.
Dawson R; University of Cape Town Lung Institute, Cape Town, South Africa.
Luetkemeyer AF; University of California San Francisco, College of Medicine, San Francisco, CA, USA.